All In Biotech

Drug Trial Radar · NCT07486960

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 20, 2026

Primary completion

Feb 17, 2027

Study completion Jul 18, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Conditions

  • Psoriatic Arthritis

Interventions

  • TulisokibartDrug

    Subcutaneous administration

  • PlaceboDrug

    Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 16Time frame: Week 16

Locations

50 sites in 8 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates, P.C. ( Site 5117)

    Sun City, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120)

    Tucson, Arizona

  • Medvin Clinical Research - Riverside ( Site 5115)

    Riverside, California

  • Cohen Medical Centers ( Site 5111)

    Thousand Oaks, California

  • Medvin Clinical Research - Tujunga ( Site 5113)

    Tujunga, California

  • Arthritis and Rheumatic Disease Specialties ( Site 5105)

    Aventura, Florida

  • International Center for Research ( Site 5124)

    Tampa, Florida

  • St. Luke's Clinic - Rheumatology - Boise ( Site 5109)

    Boise, Idaho

  • Johns Hopkins University Division of Rheumatology ( Site 5132)

    Baltimore, Maryland

  • Arthritis and Rheumatism Associates - Rockville ( Site 5127)

    Rockville, Maryland

  • Kansas City Physician Partners ( Site 5119)

    Kansas City, Missouri

  • Physician Research Collaboration, LLC ( Site 5102)

    Lincoln, Nebraska

  • Joseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 5106)

    Brooklyn, New York

  • Joint and Muscle Research Institute ( Site 5108)

    Charlotte, North Carolina

  • Altoona Center for Clinical Research ( Site 5110)

    Duncansville, Pennsylvania

  • Perelman Center for Advanced Medicine ( Site 5134)

    Philadelphia, Pennsylvania

  • Articularis Healthcare Group dba: Low Country Rheumatology ( Site 5128)

    Summerville, South Carolina

  • Greater Houston Rheumatology ( Site 5103)

    Houston, Texas

  • Centre Rhumatologie De L'Est ( Site 5201)

    Rimouski, Quebec, Canada

  • Centre de Recherche Musculo-Squelettique ( Site 5202)

    Trois-Rivières, Quebec, Canada

  • Centro de Estudios GyC ( Site 8206)

    Santiago, Region M. de Santiago, Chile

  • Enroll SpA ( Site 8203)

    Santiago, Region M. de Santiago, Chile

  • Clinica Dermacross ( Site 8200)

    Santiago, Region M. de Santiago, Chile

  • CECIM ( Site 8205)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 8212)

    Santiago, Region M. de Santiago, Chile

  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 8201)

    Santiago, Region M. de Santiago, Chile

  • Clinica de la Costa S.A.S. ( Site 8301)

    Barranquilla, Atlántico, Colombia

  • Centro de investigacion en reumatologia y especialidades medicas SAS (CIREEM SAS) ( Site 8306)

    Bogota, Cundinamarca, Colombia

  • Fundación Valle del Lili ( Site 8302)

    Cali, Valle del Cauca Department, Colombia

  • Rheumatologische Schwerpunktpraxis ( Site 6405)

    Berlin, Germany

  • HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg G ( Site 6404)

    Hamburg, Germany

  • Rheuma-Research Lausitz ( Site 6409)

    Cottbus, Brandenburg, Germany

  • Rheumazentrum Ruhrgebiet ( Site 6400)

    Herne, North Rhine-Westphalia, Germany

  • MICS Centrum Medyczne Bydgoszcz ( Site 6907)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy ( Site 6904)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • MICS Centrum Medyczne Torun ( Site 6903)

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Zespół Poradni Specjalistycznych Reumed Filia nr 1 Wallenroda ( Site 6901)

    Lublin, Lubusz Voivodeship, Poland

  • MICS Centrum Medyczne Warszawa ( Site 6905)

    Warsaw, Masovian Voivodeship, Poland

  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im.Prof. El. Reicher-ul.Spartanska 1 ( Site 6906)

    Warsaw, Masovian Voivodeship, Poland

  • Hospital Vall d' Hebron ( Site 7101)

    Barcelona, Spain

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.